ABOUT US
Suzhou LMBIO Co.
TIL therapy, as an innovative treatment for solid tumors, has officially begun commercialization with the approval of the world's first solid tumor cell therapy product, Amtagvi. Compared with other immunotherapies such as CAR-T/PD-1/PD-L1 antibodies, TIL therapy has the characteristics of multi-target, strong tumor tendency and infiltration ability, and minimal side effects. It is an innovative direction for solid tumor treatment with broad prospects. At present, the Phase I clinical trial of LM103 injection, a TIL product of Blue Horse Medical, has been launched at Peking University Cancer Hospital.
The company is committed to the mission of "focusing on the Chinese market, developing and producing high-quality products that are affordable for the Chinese people", and striving to build a "domestically advanced platform for the research and development of new cell immunotherapy drugs and industrialization".

Company Culture
-
Vision
To become a leading R&D platform for new cellular immunotherapy drugs and industrialisation in China
-
Mission
To develop and produce high quality products that are affordable to the Chinese people, based on the Chinese market
-
Values
Efficient, collaborative, decent, inclusive
Investors
LMBIO has received investments from well-known venture capital institutions at home and abroad, including Huagai Capital, Boyuan Capital IDG and Sugao New Venture Capital, providing sufficient financial support for the development and clinical translation of TILs. At the same time, it will also provide rich corporate and medical resources for Blue Horse Medical's TILs development and translation.
Since its inception, LMBIO has completed two rounds of funding and will reach tens of millions of dollars in pre-Series A funding in March 2022. The founding team has been deeply involved in TILs for many years and has extensive experience in developing a pipeline of related products at the largest TIL therapy company in the US.



